Home > Name List By e > Everolimus

CAS No 159351-69-6 , Everolimus

  • Name: Everolimus
  • Synonyms: SDZRAD;Everolimus; RAD-001; 42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin; Certica; Certican; Rapamycin, 42-O-(2-hydroxyethyl)-; CERTICAN(R);42-O-(2-Hydroxyethyl)-rapamycin;
  • CAS Registry Number:
  • Melting Point: NA
  • Density: 1.18 g/cm3
  • Refractive index: 1.548
  • Water Solubility: Soluble in DMSO and ethanol, up to about 25 mg/mL
  • Safety Statements: R48/25,
  • Hazard Symbols: T:;
  • Molecular Weight: 958.22
  • InChI: InChI=1/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
  • Risk Statements: S45,
  • Molecular Formula: C53H83NO14
  • Molecular Structure:CAS No:159351-69-6 Everolimus

Related products

Search by region :

Select to

159351-69-6 Everolimus;RAD001; SDZ-RAD; Certican; Zortress; Afinitor;RAD 001

  • Everolimus (RAD001) also known as SDZ-RAD, Certican, Zortress, Afinitorm is MTOR inhibitor with IC50 of 0.63 nM. http://www.chemscene.com/Everolimus.html
  • United States ChemScene, LLC [Manufacturer]
  • Tel: 732-484-9848
  • Fax: --
  • Address: 11 Deer Park Drive, Suite 102D, Monmouth Junction, NJ 08852 Monmouth Junction,New JerseyUnited States
Contact Supplier

159351-69-6 Everolimus

  • we can offer bulk pharmaceutical Everolimus CAS NO.159351-69-6 which used as Immunosuppressive agent. I also enclose you our product list as below and pls feel free to contact us for your any demands Naftopidil CAS no.57149-07-2, Rosiglitazone maleat...
  • China Chengdu Yuyang High-Tech Development Co.,Ltd [Manufacturer]
  • Tel: 86-28-61777709
  • Address: No,88,West Guoning Road Chengdu,SichuanChina
Contact Supplier

159351-69-6 Everolimus

Contact Supplier

159351-69-6 Everolimus

  • China Xingcheng Chempharm Co., Ltd [Manufacturer]
  • Tel: +86-576-88525005/ +86-576-88886292
  • Fax: +86-576-88225056
  • Address: B Area, 10F, Yaoda Mansion, 289, Shifu Road, Taizhou, Zhejiang, China 318000 null,nullChina
Contact Supplier

159351-69-6 EVEROLIMUS

Contact Supplier

159351-69-6 Everolimus

  • China YiPeng Chemical [Manufacturers]
  • Tel: 571 85376369
  • Fax: 571 88233092
  • Address: Building 4,High-tech Industrial Park,No. 588 Feijiatang Road,Xiacheng District, Hangzhou, China null,ZheJiangChina
Contact Supplier

159351-69-6 Everolimus

Contact Supplier

159351-69-6 Everolimus

  • China Wuxi Mizat Chemical Technology Co., Ltd. [Manufacturer]
  • Tel: +86-510-86106900/ +86-510-86125752
  • Fax: +86-510-86125752
  • Address: No.205,zhencheng Road,
    HI-TECT District,
    Wuxi, Jiangsu,China null,nullChina
Contact Supplier

159351-69-6 Everolimus

  • China Boronsyn Co.,Ltd [Manufacturer]
  • Tel: +86-21-58407925
  • Fax: +86-21-58408291
  • Address: 1213 JunMin Road,Pudong,China null,nullChina
Contact Supplier

159351-69-6 Everolimus

Contact Supplier

Select to

2/6
Previous 1 2 3 4 5 6 Next
References of Everolimus
Title: Everolimus
CAS Registry Number: 159351-69-6
CAS Name: 42-O-(2-Hydroxyethyl)rapamycin
Synonyms: 40-O-(2-hydroxyethyl)rapamycin
Manufacturers' Codes: RAD-001; SDZ RAD
Trademarks: Certican (Novartis)
Molecular Formula: C53H83NO14
Molecular Weight: 958.22
Percent Composition: C 66.43%, H 8.73%, N 1.46%, O 23.38%
Literature References: Macrolide immunosuppressant; derivative of rapamycin, q.v. Inhibits cytokine-mediated lymphocyte proliferation. Prepn: S. Cottens, R. Sedrani, WO 9409010; eidem, US 5665772 (1994, 1997 both to Sandoz). Pharmacology: W. Schuler et al., Transplantation 64, 36 (1997). Whole blood determn by LC/MS: N. Brignol et al., Rapid Commun. Mass Spectrom. 15, 898 (2001); by HPLC: S. Baldelli et al., J. Chromatogr. B 816, 99 (2005). Clinical pharmacokinetics in combination with cyclosporine: J. M. Kovarik et al., Clin. Pharmacol. Ther. 69, 48 (2001). Clinical study in prevention of cardiac-allograft vasculopathy: H. J. Eisen et al., N. Engl. J. Med. 349, 847 (2003). Review: F. J. Dumont et al., Curr. Opin. Invest. Drugs 2, 1220-1234 (2001); B. Nashan, Ther. Drug Monit. 24, 53-58 (2002).
Therap-Cat: Immunosuppressant.
Keywords: Immunosuppressant.